^
    17h
    Improving Care for Rural Patients With Solid Tumors (clinicaltrials.gov)
    P=N/A, N=320, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    20h
    A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    21h
    Shared PRAME epitopes are T-cell targets in NUT carcinoma. (PubMed, J Immunother Cancer)
    PRAME is highly and frequently expressed in NUT carcinoma, and the most common oncoprotein causing NUT carcinoma, BRD4::NUTM1, contributes to these high PRAME levels. PRAME epitopes presented by HLA class I are a previously unrecognized therapeutic vulnerability for NUT carcinoma that warrants clinical trials testing PRAME-targeted immunotherapies in this neglected patient population.
    Journal • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • NSD3 (Nuclear Receptor Binding SET Domain Protein 3) • PRAME (Preferentially Expressed Antigen In Melanoma) • BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1) • BRD3 (Bromodomain Containing 3)
    |
    brenetafusp (IMC-F106C)
    1d
    Prevalence and prognostic impact of HPV, EBV, and HIV in head and neck squamous cell carcinoma in the Brazilian Amazon cohort. (PubMed, Clin Transl Oncol)
    TP53 and EGFR gene mutations were associated with more aggressive cancer phenotypes, leading to a 2.6-fold increase in the risk of death.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation
    1d
    PD-L1 in Oral Cavity Cancers-Audit for Tertiary Care Center in India. (PubMed, Indian J Surg Oncol)
    This is one of the first studies evaluating data on the expression of PDL-1 in oral cavity cancers in the Indian population and the factors affecting it. The data provides novel insights into many factors potentially affecting the expression of PDL-1 in oral cavity cancers and in the future, can be of help in developing treatment plans with various immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    1d
    Spatial Proteomics Reveals Layer-Specific Molecular Landscapes and KRT17-Mediated Inflammatory Crosstalk in Tongue Oral Lichen Planus. (PubMed, Br J Dermatol)
    Our study uncovers layer-specific molecular landscapes in tongue OLP and identifies KRT17 as a candidate implicated in immune-epithelial crosstalk, providing novel insights into pathogenesis and a potential direction for future therapeutic exploration.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • ASS1 (Argininosuccinate synthase 1) • KRT17 (Keratin 17) • IL1B (Interleukin 1, beta) • PHGDH (Phosphoglycerate Dehydrogenase) • IL16 (Interleukin 16) • RAC2 (Rac Family Small GTPase 2)
    1d
    FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov)
    P1/2, N=260, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    FGFR2 overexpression
    |
    bemarituzumab (AMG 552)
    1d
    MACS: Mental Health App for Cancer Survivors Study (clinicaltrials.gov)
    P=N/A, N=1, Terminated, University of Wisconsin, Madison | Active, not recruiting --> Terminated; App developer is no longer in business
    Trial termination
    2d
    Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=7, Completed, Godavari Biorefineries Limited | Not yet recruiting --> Completed | N=27 --> 7 | Trial completion date: Jan 2023 --> Jan 2026 | Trial primary completion date: Dec 2022 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    2d
    SUSPECT2: Lymph Drainage Mapping for Tailoring Elective Nodal Irradiation in Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=90, Active, not recruiting, The Netherlands Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Jan 2026
    Enrollment closed • Trial primary completion date
    2d
    Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov)
    P2, N=50, Completed, Yale University | Active, not recruiting --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • Gilotrif (afatinib)
    2d
    Cisplatin disrupts OCT1-DNMT1-piRNA epigenetic regulatory axis to suppress GAB2-mediated aggressiveness in OSCC. (PubMed, Arch Biochem Biophys)
    Furthermore, GAB2 overexpression reversed these effects and desensitized cisplatin by activating NF-κB-mediated JNK suppression. Overall, cisplatin actively remodels the OCT1-DNMT1-piR-hsa-30937 axis by regulating piRNA expression, which in turn potentiates cisplatin cytotoxicity by attenuating GAB2-mediated survival signaling in OSCC.
    Journal
    |
    DNMT1 (DNA methyltransferase 1) • SLC22A1 (Solute Carrier Family 22 Member 1)
    |
    cisplatin